Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
2680 articles with Eli Lilly and Company
-
New England Journal of Medicine Publishes Phase 1/2 Data for Retevmo™ (selpercatinib) in Advanced RET-Driven Lung and Thyroid Cancers
8/27/2020
Data demonstrated durable objective responses across both the RET fusion-positive NSCLC and RET-altered thyroid cancer patient cohorts
-
Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement
8/18/2020
Eli Lilly and Company and Innovent Biologics, Inc. announced a global expansion of their strategic alliance for TYVYT®, an anti-PD-1 monoclonal antibody immuno-oncology medicine that was co-developed by Innovent and Lilly in China.
-
Innovent and Lilly Announce Expansion of TYVYT® (Sintilimab Injection) Licensing Agreement
8/18/2020
Innovent Biologics, Inc. and Eli Lilly and Company announced an expansion of their strategic alliance for TYVYT®, an anti-PD-1 monoclonal antibody immuno-oncology medicine that was co-developed by Innovent and Lilly in China.
-
Eli Lilly will aim a checkpoint inhibitor it co-developed for the Chinese market at the United States and other western markets.
-
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT® (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
8/12/2020
Innovent Biologics, Inc. jointly announced with Eli Lilly and Company that the National Medical Products Administration of China has accepted the supplemental New Drug Application for TYVYT® in combination with Gemzar® and platinum as first-line therapy in squamous non-small cell lung cancer.
-
Pieris and Lilly Enter Into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer
8/10/2020
Pieris Pharmaceuticals, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate the safety and efficacy of combining Pieris' PRS-343, a 4-1BB/HER2 bispecific for HER2-positive tumors
-
Clinical Catch-Up: August 3-7
8/10/2020
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look. -
Innovent and Lilly Release Clinical Trial Results of Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous NSCLC in an Oral Presentation at IASLC WCLC 2020
8/8/2020
Innovent Biologics, Inc. announced with Eli Lilly and Company that interim analysis data from ORIENT-11 were released today in an oral presentation at the IASLC World Conference on Lung Cancer 2020 Virtual Presidential Symposium.
-
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
8/5/2020
Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
-
Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)
8/3/2020
More than 40 percent of coronavirus deaths in the U.S. linked to long-term care facilities; urgent need for therapeutic strategies to prevent COVID-19 in this vulnerable population
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
-
Lilly Reports Second-Quarter Financial Results, Raises EPS Guidance
7/30/2020
Revenue in the second quarter of 2020 declined 2 percent, comprised of volume growth of 6 percent, a 7 percent decrease in realized prices and a 1 percent unfavorable impact from foreign exchange rates.
-
Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
7/30/2020
Jardiance (empagliflozin) significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction
-
Boehringer Ingelheim and Eli Lilly and Company announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
-
Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China
7/28/2020
Hutchison China MediTech Limited and Eli Lilly and Company announce an amendment to the 2013 License and Collaboration Agreement on Fruquintinib with Lilly Shanghai, an affiliate of Lilly.
-
Zentalis Pharmaceuticals Enters into Clinical Collaboration with Eli Lilly and Company to Evaluate its Oral SERD ZN-c5 in Combination with Abemaciclib, a CDK4 and 6 Inhibitor
7/27/2020
Zentalis Pharmaceuticals, Inc. announced a clinical collaboration agreement with Eli Lilly and Company in which Zentalis will evaluate the combination of ZN-c5, the Company’s oral selective estrogen receptor degrader product candidate, and Verzenio®, Lilly’s CDK4 and 6 inhibitor, in patients with ER+/HER2- advanced breast cancer.
-
Data from Lilly at Alzheimer's Association International Conference 2020® (AAIC® 2020) to Showcase Clinical Advances in Alzheimer's Research
7/21/2020
Highlights include data that advance the understanding of Alzheimer's disease across the spectrum including early and accurate detection, diagnosis and treatment
-
Clinical Catch-Up: July 13-17
7/20/2020
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.